McKesson Corporation

MCK

$916.16

-0.57%

2026-09-04 12:08:00 EDT-$5.22

Healthcare

Medical - Distribution

NYSE

Active Trading

McKesson Corporation is a prominent global provider of healthcare services, operating extensively in both the United States and international markets. Its diverse ...

Price Action of MCK

$916.16

-0.57%-$5.22

High—

Low—

52W High-8.1%

Rel. vol—

Interval

Range2.6h

Volume—SMA5SMA10

—

McKesson Corporation, founded in 1833 by John McKesson and Charles Olcott, is a leading healthcare services company headquartered in Irving, Texas. With approximately 43,000 employees, it operates across North America and Europe, delivering a significant portion of pharmaceutical products used in North America. The company is organized into four key ...McKesson Corporation, founded in 1833 by John McKesson and Charles Olcott, is a leading healthcare services company headquartered in Irving, Texas. With approximately 43,000 employees, it operates across North America and Europe, delivering a significant portion of pharmaceutical products used in North America. The company is organized into four key segments: U.S. Pharmaceutical, which distributes branded, generic, specialty, biosimilar, and OTC medications, and provides support to oncology practices and pharmacies; International, serving wholesale, institutional, and retail clients in 13 European countries and Canada; Medical-Surgical Solutions, supplying medical-surgical products and logistics management; and Prescription Technology Solutions, which offers medication access and adherence solutions by connecting pharmacies, providers, payers, and biopharma companies. McKesson's financial metrics indicate a market cap of over $101 billion, a gross profit margin of approximately 3.6%, and a net profit margin of 1.1%, reflecting its low-margin, high-volume distribution model. The company has a strong commitment to innovation, as seen in its technology solutions and strategic partnerships. Key leadership includes CEO Brian S. Tyler, who has held various roles since 1997. McKesson also emphasizes corporate responsibility, aiming to advance health outcomes for all, and has a rich history of evolution, including mergers such as McKesson & Robbins and McKessonHBOC. The company continues to adapt to the changing healthcare landscape, focusing on specialty pharmaceuticals, biopharma services, and technology-driven solutions to improve patient care.ExpandCollapse

Founded

1833

Employees

42300

CEO

Brian S. Tyler

Full Name

McKesson Corporation

Sector

Healthcare

Industry

Medical - Distribution

ROE

-194.39%

Market Cap

$106.82B

Current Ratio

0.89

WACC

5.79%

ROIC

43.51%

Contact Information

https://www.mckesson.com

972 446 4800

6555 State Highway 161, Irving, TX 75039

Key Metrics of MCK

Snapshot

Latest / TTM · 6 periods

Market Cap

$106.82B

ROCE

37.0%

EV / EBITDA

16.01x

-5.1% YoY

FCF Yield

5.7%

+0.7% YoY

Cash Conversion Cycle

-7.6d

Current Ratio

0.89

Quick take

TTM —

Current ratio below 1.0

Negative working capital

Financial Highlights of MCK

Profitability trend

Latest / TTM · 6 periods

Gross Margin

3.6%

Net Margin

1.1%

P/E Ratio

24.55x

n/a

Debt / Equity

-2.76

n/a

Current Ratio

0.89

Dividend Yield

0.4%

Understanding

TTM —

Current ratio below 1.0

Calendar of MCK

Upcoming

Oct 1, 2026In 27 days
Dividend payment
$3.28 per share
Mar 31, 2027
FY2027 · Estimated annual results
Est. EPS $44.61 · Revenue $431.96B · 9 analysts
Dec 30, 2027
Q3 FY2028 · Estimated results
Est. EPS $12.66 · Revenue $119.82B · 8 analysts
Mar 30, 2028
Q4 FY2028 · Estimated results
Est. EPS $14.23 · Revenue $109.53B · 9 analysts

Recent history

Sep 1, 2026
Ex-dividend date
$3.28 per share
Aug 5, 2026
Q1 FY2027 · Results reported
EPS $5.15 · Revenue $105.38B
View filing
May 8, 2026
FY2026 · Annual results
EPS $38.38 · Revenue $403.43B
View filing
Feb 4, 2026
Q3 FY2026 · Results reported
EPS $9.59 · Revenue $106.16B
View filing
Nov 6, 2025
Q2 FY2026 · Results reported
EPS $8.92 · Revenue $103.15B
View filing
Aug 6, 2025
Q1 FY2026 · Results reported
EPS $6.25 · Revenue $97.83B
View filing

Financial Statements of MCK

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$403.4B	+12.4%	+9.4%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$4.8B	+44.5%	-63.5%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	+3.6%	+3.7%	-16.7%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	+1.6%	+31.4%	-46.4%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	+1.2%	+28.6%	-66.6%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$5.4B	+3.5%	-110.3%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	+1.3%	-7.9%	-109.4%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	-396.6%	-11.3%	+30.4%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	0.85x	-5.1%	+4.6%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$82.3B	+9.6%	+7.3%

Actual vs Estimate

A Mar 31Q Dec 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	38.38 vs 39.01	-1.6%	5.15 vs 12.66	-59.3%
Revenue Surprise	$403.4B vs $408.5B	-1.2%	$105.4B vs $119.8B	-12.1%

Insider Transactions of MCK

Acquisitions (A)

Since Jul 22, 2026

Disposals (D)

Since Jul 22, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Aug 10, 2026	Lerman Bradley E	director	Common Stock	D	301	$892.33
Aug 7, 2026	Srinivasan Ramesh (NMN)	officer: EVP and Chief Strategy Officer	Restricted Stock Units (RSUs)	A	368	—
Aug 1, 2026	Srinivasan Ramesh (NMN)	officer: EVP and Chief Strategy Officer	Common Stock	—	0	—
Aug 1, 2026	Srinivasan Ramesh (NMN)	officer: EVP and Chief Strategy Officer	Restricted Stock Units (RSUs)	—	316	—
Jul 22, 2026	Hinton James H.	director	Restricted Stock Units (RSUs)	A	277	—

Earnings Call Transcript of MCK

1 transcript segments

Q1 2027

Unknown Speaker

Operator: Please standby. Welcome to McKesson's First Quarter Fiscal 27 Earnings Conference Call. Please be advised that today's conference is being recorded. At this time, I would like to turn the call over to Paul Eckison, SVP of Corporate Finance and Investor Relations. Please go ahead. Jeni Dominguez: Thank you, operator. Good afternoon, and welcome, everyone, to McKesson's First Quarter Fiscal 27 Earnings Call. Todd, I am joined by Brian S. Tyler, our Chair and Chief Executive Officer along with Kenny K. Cheung, our chief financial officer. Brian will lead off, followed by Kenny, and then we will move to a question and answer session. Today's discussion will include forward looking statements such as forecasts on McKesson's operations and future results. Please refer to the cautionary statements in today's earnings release and presentation slides available on our website at investor.mckesson.com. And to the risk factors section of our most recent annual and periodic SEC filings. For additional information concerning risk factors that could cause our actual results, to materially differ from those in our forward looking statements. Information about non GAAP financial measures that we will discuss during this webcast, including a reconciliation of those measures to GAAP results, can be found in today's earnings release and presentation slides. and guidance assumptions. The presentation slides also include a summary of our results for the quarter With that, let me turn it over to Brian. Brian S. Tyler: Good afternoon, everyone, and thank you for joining our call. Earlier today, we reported strong fiscal first quarter results. Reflecting broad based momentum across the enterprise and the disciplined execution of our teams. Revenues increased 8% to $105 billion and adjusted earnings per diluted share increased 20% to $9.93 both results exceeding our expectations. During the quarter, 3 of our reporting segments delivered double digit operating profit growth. Reflecting the strength of our core operating businesses. This performance is underpinned by good stable utilization and volume growth, and is reinforced by our differentiated portfolio of solutions, our focus and the execution of our strategy. We are pleased with the strength of our first quarter performance. Which gives us the confidence to raise full year adjusted earnings per diluted share guidance to $44.20 to $45. From the prior range of $43.80 to $44.60. Before I share an update on how we advanced our strategic priorities during the quarter, I wanted to take a moment to recognize an important leadership transition. And recognize someone in the room with me today. Kenny K. Cheung, who is our new chief financial officer. Kenny joined us in May, and we are excited to have him as part of team McKesson. Following a thoughtful and comprehensive search, we are confident that Kenny is the right leader for McKesson. He brings extensive experience across finance and operations, with a focus on …

Leadership Team of MCK

17 executives

Name	Title	Compensation	Gender	Year Born	Status
Brian S. Tyler	CEO & Chairman	USD 7,011,842	Male	1967	Active
Britt J. Vitalone	Executive Officer	USD 3,136,731	Male	1969	Active
Martin Koffel	Executive Officer	USD 3,136,731	Male	1939	Active
Kenny K. Cheung	Executive Vice President & Chief Financial Officer	USD 2,681,328	Male	1982	Active
Michele Lau	Executive Vice President & Chief Legal Officer	USD 1,944,669	Female	1976	Active
LeAnn Smith	Executive Vice President & Chief Human Resources Officer	USD 1,753,129	Female	1975	Active
Thomas L. Rodgers	Executive Vice President and Chief Strategy & Business Development Officer	USD 1,635,853	Male	1971	Active
Paula Adkison	Senior Vice President of Corporate Finance, Investor Relations & Strategic Finance	—	—	—	Active
Saralisa C. Brau	Corporate Secretary	—	—	—	Active
Yiyi Frechette	Director of Investor Relations	—	—	—	Active
Todd Kleinow	VP of Strategic Distribution & Operations	—	Male	—	Active
Kirk Kaminsky	Executive Vice President & Group President of North American Pharmaceutical Services	—	Male	—	Active
Napoleon Rutledge Jr.	Senior Vice President, Controller & Chief Accounting Officer	—	Male	1973	Active
Jeni Dominguez	Head of Investor Relations	—	Female	—	Active
Paul A. Smith	Senior Vice President of Taxes	—	—	—	Active
Francisco Fraga	Executive Vice President, Chief Information Officer & Chief Technology Officer	—	Male	1973	Active
Stanton McComb	President of Medical-Surgical	—	Male	—	Active

Recent News of MCK

Zacks Investment Research8/10/2026Neutral

Here's Why McKesson (MCK) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

MarketBeat8/8/2026Neutral

McKesson Q1 Earnings Call Highlights

McKesson NYSE: MCK reported fiscal first-quarter 2027 results that exceeded its expectations, citing broad-based momentum across its operating businesses and prompting the healthcare services company to raise its full-year adjusted earnings outlook.

Seeking Alpha8/8/2026Neutral

McKesson: Solid Q1 Earnings And Management Execution (Rating Upgrade)

McKesson delivered strong Q1 results, with EPS up 20% and revenues rising 7.7% while modestly raising FY27 EPS guidance. I see GLP-1-driven momentum decelerating alongside a broader dip in the company's top-line growth profile. The Wellverse spin-off and prior divestitures are streamlining MCK, potentially justifying a premium multiple versus peers.

Zacks Investment Research8/7/2026Neutral

McKesson (MCK) is an Incredible Growth Stock: 3 Reasons Why

McKesson (MCK) could produce exceptional returns because of its solid growth attributes.

Zacks Investment Research8/6/2026Neutral

MCK Stock Up as Q1 Earnings Beat on Specialty Growth, Guidance Raised

McKesson shares rise after fiscal Q1 earnings and revenues beat estimates, powered by specialty growth, as the company raises its 2027 EPS outlook.

Historical Employee Count of MCK

Current

43,000

Change

-4.44%

Minimum

43,000

Maximum

75,000

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Mar 31, 2026	43,000	10-K	May 8, 2026	View
Mar 31, 2025	45,000	10-K	May 9, 2025	View
Mar 31, 2024	51,000	10-K	May 8, 2024	View
Mar 31, 2023	51,000	10-K	May 9, 2023	View
Mar 31, 2022	75,000	10-K	May 9, 2022	View

Related stocksMedical - Distribution

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

McKesson Corporation